R 1065
Alternative Names: VMR 003; VR 1065Latest Information Update: 01 Aug 2002
At a glance
- Originator Roche; Vernalis Group
- Class Obesity therapies
- Mechanism of Action 5-HT2C serotonin receptor agonists; G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 01 Aug 2002 Discontinued - Phase-I for Obesity in United Kingdom (unspecified route)
- 29 May 2002 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)
- 22 May 2002 Preclinical trials in Obesity in Switzerland (unspecified route)